Bone Mineral Density in Women Living with Complete Androgen Insensitivity Syndrome and Intact Testes or Removed Gonads

Silvano Bertelloni a, Maria C. Meriggiola b, Elenora Dati d, Antonio Balsamo c, Giampiero I. Baroncelli a

a Pediatric Division, Department of Obstetrics, Gynecology and Pediatrics, Azienda Ospedaliero-Universitaria Pisana, Pisa, b Gynecology and Physiopathology of Reproduction and c Pediatric Endocrine Unit, Department of Pediatrics, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, and d Division of Pediatrics, San Giuseppe Hospital, ASL 11, Empoli, Italy

Abstract

Complete androgen insensitivity syndrome (CAIS) is due to complete androgen resistance in androgen-dependent tissues. Since androgens are involved in growth, development, and mass maintenance of the skeleton, bone health may be a relevant clinical issue for improving quality of life of women living with CAIS. Bone mineral density (BMD) in women with CAIS and intact gonads has been reported in a normal range, although exceptions are known showing a low BMD mainly at the lumbar level. In women with CAIS and removed gonads, BMD is usually reduced at both the lumbar spine and femoral neck. However, the fracture risk remains largely unknown. In women with CAIS, hormonal replacement therapy may improve BMD, but it does not normalize it. Several factors may be operative (e.g., loss of AR signaling at the bone level, gonadal removal, and age at surgery [before or after attainment of the peak bone mass], inadequate sex steroid replacement therapy, poor compliance with hormonal treatment, high serum FSH levels, lack of testicular protein hormones after gonadal removal), but they are poorly evaluated. In conclusion, the maintenance of testes may represent a strategy to improve bone health in women with CAIS, but a strict follow-up to monitor the cancer risk is mandatory mainly from their 20s onwards. Optimal sex steroid substitutive therapy in adolescence and adulthood is a key factor to improve BMD status in women with CAIS and removed gonads, but conclusive data on optimal management are lacking.

Sex steroids act on the growing skeleton, contribute to maintain skeletal homeostasis, and play a key role in some aspects of bone dimorphism between males and females from puberty onward [Parfit, 1994; Seeman, 2001; Baroncelli and Bertelloni, 2009]. Sex steroid effects on bone are mainly exerted by activations of specific peripheral receptors (i.e., androgen receptor [AR] and estrogen receptor-α [ER-α]) in osteoblasts, osteoclasts, osteocytes, and growth plate chondrocytes as well as an age-related sex-specific hormonal milieu [Vanderschueren et al., 2004; Baroncelli...
and Bertelloni, 2009; Rochira and Carani, 2009; Callewaert et al., 2010; Laurent et al., 2014]. Therefore, the skeletal phenotype of the 2 sexes and bone health are influenced by an adequate sex steroid production and metabolism during life as well as an optimal response to their peripheral actions. Testosterone is the main androgen hormone secreted by the testes; it may also be considered as a pro-hormone, as it can be metabolized to 5α-dihydrotestosterone by 5α-reductase-2 and to 17β-estradiol by P450 aromatase [Baroncelli and Bertelloni, 2009; Rochira and Carani, 2009]. Thus, testosterone may act via AR signaling or indirect by ER-α signaling. Different actions of estrogens and androgens on skeletal muscles and mechatnostat sensitivity may also be involved in bone health and sexual dimorphism between males and females [Frost and Schönau, 2000].

Complete androgen insensitivity syndrome (CAIS) is caused by mutations in the AR gene, determining loss of AR function and complete androgen resistance in androgen-dependent tissues; it affects 1 in 20,000–90,000 neonates [Hughes et al., 2012]. Women with CAIS present with a 46,XY karyotype, normal secreting testes, and normal external female genitalia and body habitus [Hughes et al., 2012]. In adult women with CAIS, reduced bone mineral density (BMD) has been reported [reviewed in Bertelloni et al., 2010]. The low BMD may be due to the impaired AR action, but the practice of removing gonads to prevent cancer risk may contribute to this finding [reviewed in Bertelloni et al., 2010]. Osteoporosis risk is a concern for women living with CAIS (www.aissg.org; www.aisia.org; www.grapsia.org), and optimal strategies to improve bone health should be developed.

This paper reviews the bone status of adult women living with CAIS who maintained their gonads or had their gonads removed.

### BMD Status in Women Living with CAIS and Intact Gonads

Very few data are available on BMD in females with CAIS and intact gonads (Table 1). Variable results have been reported, but a tendency to reduced BMD values has been found, mainly at the lumbar spine. Lumbar BMD scans below –2.5 standard deviations (SD) (that is the cut-off to define osteoporosis according to WHO) [NIH Consensus, 2001] were reported in 5/10 women [Muñoz-Torres et al., 1995; Bertelloni et al., 1998; Mizunuma et al., 1998; Tian et al., 2005; Danilovic et al., 2007; Chin et al., 2012] (Table 1). All femoral neck measurements were within the normal range, even though below the 0 SD in 6/9 persons [Soule et al., 1995; Muñoz-Torres et al., 1995; Bertelloni et al., 1998; Mizunuma et al., 1998; Tian et al., 2005; Danilovic et al., 2007; Chin et al., 2012] (Table 1).

The discrepancy among the various reports (Table 1) is unclear, but issues such as reference values for DXA (dual-energy X-ray absorptiometry) scans, auxological parameters, vitamin D status, diet, and life styles may be involved, but they were poorly explored. In addition, molecular analysis of the AR gene was not always performed.

Recently, we examined 10 adult women with proven CAIS and intact gonads [Meriggiola et al., 2015]. Lumbar

---

**Table 1.** BMD in late adolescents/young women with CAIS and intact gonads

<table>
<thead>
<tr>
<th>Reference</th>
<th>Age, years</th>
<th>AR gene analysis</th>
<th>BMD, SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soule et al. [1995]</td>
<td>29</td>
<td>no</td>
<td>–1.5</td>
</tr>
<tr>
<td>Muñoz-Torres et al. [1995]</td>
<td>17</td>
<td>no</td>
<td>–4.1</td>
</tr>
<tr>
<td>Mizunuma et al. [1998]</td>
<td>19</td>
<td>no</td>
<td>–0.8</td>
</tr>
<tr>
<td>Bertelloni et al. [1998]</td>
<td>28</td>
<td>no</td>
<td>–3.1</td>
</tr>
<tr>
<td>Sobel et al. [2006]</td>
<td>17</td>
<td>?</td>
<td>–2.9</td>
</tr>
<tr>
<td>Danilovic et al. [2007]</td>
<td>24</td>
<td>yes</td>
<td>–1.6a</td>
</tr>
<tr>
<td>Chin et al. [2012]</td>
<td>15</td>
<td>yes</td>
<td>–0.6</td>
</tr>
</tbody>
</table>

BMD, Bone mineral density; SD, standard deviation. a In respect to calculated apparent volumetric BMD.
BMD values were below the mean, although not significantly reduced, while femoral BMD was slightly above the mean (Fig. 1, open columns). No woman showed lumbar or femoral BMD below −2.5 SD. Lumbar BMD was significantly reduced in comparison with femoral neck BMD (Fig. 1, open columns).

These results suggest that bone health seems not to be grossly impaired in the majority of adults with CAIS who maintained their gonads. Indeed, lumbar BMD is more affected than femoral BMD. Thus, a particular sensibility of trabecular bone to AR signaling impairment seems to be operative [Sobel et al., 2007; Danilovic et al., 2007; Bertelloni et al., 2010]. In this regard, experimental studies showed that osteoblasts and osteocytes are the target cells for AR-mediated maintenance of trabecular bone as well as the main players of coupling between bone matrix synthesis and mineralization [Vanderschueren et al., 2004; Callewaert et al., 2010; Sinnesael et al., 2012].

**BMD Status in Women Living with CAIS and Removed Gonads**

Reduced BMD has been clearly reported in adolescents and women with CAIS and removed gonads with some differences among the various studies (Table 2) [Soule et al., 1995; Vered et al., 1997; Bertelloni et al., 1998; Marcus et al., 2000; Tian et al., 2005; Sobel et al., 2006].
2006; Danilovic et al., 2007; Han et al., 2008; Taes et al., 2009]. Also in this group, lumbar BMD was usually more affected than femoral neck BMD (Table 2). Some studies included single individuals [Vered et al., 1997; Taes et al., 2009] or small samples [Soule et al., 1995; Bertelloni et al., 1998; Sobel et al., 2006; Danilovic et al., 2007], but such findings have been confirmed in relative large series for this rare condition [Marcus et al., 2000; Han et al., 2008].

BMD scans were carried out in heterogeneous populations regarding age at gonadectomy, hormonal replacement therapy (HRT; formulations and doses), and certainty of diagnosis at the molecular level (Table 2). In one study, the diagnosis was self-reported by participants [Marcus et al., 2000]. Therefore, subjects affected by other 46,XY disorders of sex development might have been enrolled in some studies. In addition, normative data to evaluate BMD did not always match with the ethnic origin of the investigated people [Sobel et al., 2006; Danilovic et al., 2007].

We measured BMD in a series of 43 women with proven CAIS and removed gonads, showing significantly reduced lumbar and femoral neck BMD (Fig. 1, black columns) [Meriggiola et al., 2015]. Lumbar BMD was significantly below femoral neck BMD (Fig. 1, black columns). In addition, both lumbar and femoral neck BMD were significantly reduced in comparison with those measured in the group of women with intact gonads (Fig. 1) [Meriggiola et al., 2015]. Albeit variable age at gonadectomy and HRT protocols were present also in our series, homogeneous DXA scans were obtained and results were compared with appropriate reference populations.

**Fracture Rate in Women Living with CAIS**

Low BMD is a major risk factor for fractures [NIH Consensus, 2001]. No data on the fracture rate are available in the literature for women with CAIS and intact testes, but we did not find any fractures in the 10 females we studied [Meriggiola et al., 2015]. A high fracture rate has been reported in the study of Marcus et al. [2000] in women with removed gonads (6/22; 27.3%). Multiple fractures also occurred in 1 out of 6 women in the study of Soule et al. [1995] and in that described by Taes et al. [2009]. In our previous series of 10 girls and adolescents, no fractures were recorded [Bertelloni et al., 1998], while 1/43 women (2.3%) of our recent adult sample reported a fracture [Meriggiola et al., 2015]. In other studies, the fracture rate was not explored. Albeit such fractures may be related to a low BMD, available data do not permit definite conclusions due to the limited number of persons enclosed in each study.

**Causes of Impaired BMD in Women Living with CAIS**

In CAIS, absent AR action at the bone tissue level may contribute per se to the low BMD values; trabecular bone seems to be mainly affected as suggested by the lower lumbar BMD in comparison with femoral neck BMD (Fig. 1; Table 1).

Impaired BMD has been related to gonadectomy followed by inappropriate HRT, poor compliance with treatment, or inadequate doses of sex steroids, typically estrogens [Soule et al., 1995; Marcus et al., 2000; Sobel et al., 2006; Danilovic et al., 2007; Han et al., 2008; Taes et al., 2009]. In fact, adults with CAIS and good HRT showed better lumbar and femoral BMD values [Han et al., 2008; Marcus et al., 2000; Meriggiola et al., 2015]. Indeed, the majority of women with CAIS and removed gonads showed only mild or no improvement of their BMD during estrogen administration mainly at the lumbar level (Fig. 2). No improvement of apparent volumetric lumbar BMD has been also observed during 2 years of 0.625 mg conjugated estrogens [Danolovic et al., 2007]. Thus, usual HRT schemes may be not optimal for bone health (doses, route of administration) or other factors may be involved.

With regard to HRT, a relevant increase of lumbar BMD during high-normal estrogen therapy has been reported in a single person, but it remained at −2.0 SDS at the end of a 5-year follow-up period (Fig. 2) [Taes et al., 2009]. In this woman, peripheral quantitative computed tomography documented estrogen-specific effects on bone envelopes, showing a gradual increase in trabecular and cortical bone density (+6.5% and +2.1%, respectively) and in cortical thickness (+3%) as the result of endosteal contraction (−1.0%) without marked influence on periosteal bone apposition [Taes et al., 2009]. Therefore, young women with CAIS may require higher doses of substitutive therapy, while the majority would receive low-normal standard doses (i.e., equivalent to 0.625–1.25 mg of conjugated estrogens) [Birnbaum and Bertelloni, 2014]. It must be considered that the recommended premenopausal adult daily dose may reach 100–200 μg of transdermal 17β-estradiol (equivalent to 2–4 mg of oral micronized 17β-estradiol or 1.25–2.5 mg of conjugated estrogens) [Bondy et al., 2007]. The route of administration and formulations may also affect the BMD status. For
example, in adolescents with Turner syndrome, transdermal estrogens determined a greater increase in BMD in respect to oral conjugated estrogens [Nabhan et al., 2009]. With regard to other factors, the elevated FSH levels in women with removed gonads, which are related to the lack of inhibins produced by the Sertoli cells [Melo et al., 2003; Audi et al., 2010], may play a role. Experimental studies indicated that osteoclastic bone resorption may be triggered in hypogonadal rodents via activation of the FSH receptor and TNFα production by bone marrow [Iqbal et al., 2006; Sun et al., 2006]. A specific FSH antibody is able to block the FSH effect on osteoclast formation in vitro and, when injected into ovariectomized mice, attenuates bone loss [Zhu et al., 2012]. Indeed, FSH serum levels in women with CAIS and intact gonads did not differ from normal adult values or were slightly elevated in a minority of subjects [Melo et al., 2003; Doehnert et al., 2015].

Finally, testicular hormones other than sex steroids may be involved in the differences between women with intact or removed gonads. For example, INSL3, the testis-specific protein hormone secreted by Leydig cells, may act on bone by inducing the expression of some key osteoblast genes for osteoblast differentiation, matrix deposition, and osteoclastogenesis. It may also act by stimulation of mineralization and/or promoting better function of the muscle-skeletal unit [Ferlin et al., 2016]. Even though the INSL3 status of women with CAIS who maintained their gonads is unknown, this hormone is obviously absent in those females who underwent gonadal removal. Surgery before or after the attainment of the peak bone mass may be an additional factor.

How to Optimize Bone Health in CAIS

Tentative indications to optimize bone health in CAIS are summarized in Table 3.

The maintenance of gonads may represent a strategy, but a strict follow-up must be warranted [Deans et al.,
2012; Wünsch et al., 2012]. These women must be fully and clearly informed about the cancer risk, and an annual follow-up of testes by ultrasound should be carried out at least from the age of 20 onward [Deans et al., 2012].

Since some women with intact gonads anyway may show reduced BMD values (Table 1), it has been suggested that this subset could benefit from treatment with additional estrogens even in the presence of intact testes [Warne et al., 2005]. Clinical data addressing this hypothesis are not available, and the safety of this procedure has not been explored.

When gonads have been removed, doses and formulations of sex steroid substitutive therapy must be optimized for women living with CAIS, recommending the use of transdermal estrogen deliveries and strictly monitoring compliance. Progestins should be avoided in these women without uterus, mainly medroxy-progesterone acetate, for its possible direct or indirect negative effects on bone [Committee Opinion, 2014].

In women with proven CAIS, testosterone is the main sex steroid hormone secreted by their gonads [Melo et al., 2003; Doehnert et al., 2015]. Thus, this hormone might be used for substitutive therapy instead of estrogens (German Clinical trials register: trials DRKS-ID DRKS00003136; https://drks-neu.uniklinik-freiburg.de), titrating the doses upon the sex steroid values reported in women with intact gonads [Doehnert et al., 2015] to take advantage of the nongenomic action of this hormone on skeletal muscle and osteoblasts [Lieberherr and Grosse, 1994; Dent et al., 2012]. At present, data supporting this approach to improve bone health are lacking. In a woman treated with testosterone undecanoate (1,000 mg i.m./90 days), we found an increase of lumbar BMD (Fig. 2), but femoral neck BMD decreased from 0.931 to 0.732 g/cm². So, more data are needed to draw some conclusions.

It should also be considered that women with CAIS may have a specific bone phenotype. Thus, female or male reference values could be inadequate to evaluate DXA scans in these persons, and only the assessment of the fracture rate in large samples will permit a true estimation of bone risk. In addition, bone geometry, strength, and shape and their inferences on bone health are poorly explored. Thus, specific longitudinal studies are needed to highlight these issues.

Finally, bone growth and maturation and bone mass accrual during prepubertal years and during mid to late adolescence, when large part of the bone mass is gained, should be better evaluated in order to obtain more information on prenatal and postnatal influences of androgens on the development of the bone phenotype, which will influence bone health during life. Furthermore, general factors (i.e., vitamin D status, calcium assumption, fitness, body weight, smoking, drinking, etc.) should be optimized in order to improve bone health in women living with CAIS as in the general population.

### Table 3. Bone health in CAIS: indications for practice and research

<table>
<thead>
<tr>
<th>BMD status</th>
<th>Actions to improve BMD</th>
<th>research agenda</th>
</tr>
</thead>
</table>
| Reduced BMD, mainly at lumbar spine, in women with removed gonads | – Maintain gonads as long as possible\(^a\)  
– Optimize estrogen therapy from puberty onward in women with removed gonads: use 17β-estradiol (transdermal) formulations and doses adequate for young adults with impaired AR action  
– Avoid administration of progestins (mainly medroxyprogesterone acetate)\(^b\)  
– Optimize intake of calcium, vitamin D, and fitness | – Supplemental estrogens in women with intact gonads and low BMD\(^c\)  
– Testosterone therapy (instead of estrogens) in women with proven CAIS diagnosis\(^d\)  
– Adjunctive INSL3 administration in women with removed gonads\(^d\) |

<table>
<thead>
<tr>
<th>Actions to improve BMD</th>
<th>research agenda</th>
</tr>
</thead>
</table>
|To be evaluated:  
– Longitudinal assessment of BMD before and after gonadectomy  
– Bone geometry, strength, and shape  
– Muscle-skeletal unit inferences  
– Bone accrual from infancy to adolescence | |

BMD, bone mineral density.

\(^a\) Gonads must be strictly followed up (by ultrasound, at least yearly).

\(^b\) There is no evidence that cyclic progesterone is beneficial in women without a uterus, but some data suggest that medoxyprogesterone acetate may have negative effects on bone.

\(^c\) To be explored; safety of high estrogen doses (if used) in CAIS should be proven and accurately monitored.

\(^d\) To be explored.
Acknowledgement

The authors wish to thank the Italian Androgen Insensitivity Syndrome Support Group (AISIA). This paper was developed under the auspices of the Italian Society for Pediatric Research.

Disclosure Statement

The authors have no conflicts of interest to declare.

References


Bone Health in CAIS

Sex Dev

DOI. 10.1159/000477599


**Note Added in Proof**

Recently, King et al. [2017] published a retrospective analysis of pre- and post-gonadectomy BMD parameters in a large sample of women with CAIS (n = 113; age at gonadectomy 13.0–16.5 years; age at latest DXA scan 31.4–36.3 years). T-score BMD at lumbar spine was −1.34 (−1.55 to −1.13; p < 0.001) and at the hip −0.3 (−0.49 to −0.12; p = 0.001). In this series, there was no relationship between age of gonadectomy and BMD. Thirty-two subjects had BMD measured before or within 2 years of gonadectomy, and mean BMD was reduced (95% CI) at the lumbar spine (T-score: −1.05 [−1.54 to −0.57]; p < 0.001) but was normal at the hip (T-score: −0.04 [−0.35 to 0.28]; p = 0.8). In addition, these authors did not report any drop in BMD in women with DXA scans both before and after gonadectomy (n = 12; 1.7–12.8 years of follow-up). Taken together, the data confirm that lumbar spine BMD is more affected than that of the hip in women living with CAIS and that bone health represents a specific need of care, allowing recommending regular BMD monitoring in all these subjects [King et al., 2017]. Indeed, the issue of true factors involved in low BMD in CAIS remains open for discussion and for further studies.

Reference